Amylyx Withdraws ALS Drug Relyvrio from Market Following Failed Trial
TL;DR Summary
Amylyx Pharmaceuticals has decided to voluntarily remove its ALS drug, Relyvrio, from the market following a failed clinical trial that showed the drug's ineffectiveness in treating amyotrophic lateral sclerosis. The company will not make the drug available to new patients and plans to transition existing patients to a free drug program. This move comes after the drug's approval by the FDA in 2022 based on a single trial, which sparked controversy. Amylyx will also reduce its staff by 70 percent and continue to study the results of the failed trial to inform future ALS research while focusing on developing a drug for Wolfram syndrome.
Topics:business#als#amylyx-pharmaceuticals#clinical-trial#drug-market-withdrawal#health-pharmaceuticals#relyvrio
- Amylyx will remove ALS drug from the market after failed trial The Washington Post
- A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Says The New York Times
- Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers FiercePharma
- ALS drug Relyvrio withdrawn from market after failed clinical trial CNN
- ALS drug will be pulled from US market after study showed patients didn't benefit ABC News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
83%
615 → 104 words
Want the full story? Read the original article
Read on The Washington Post